NCT05497778View on ClinicalTrials.gov

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 21, 2022

Primary Completion Date

February 2, 2027

Study Completion Date

February 2, 2027

Conditions
Pancreas Cancer
Interventions
DRUG

Gemcitabine

Given by IV (vein)

DRUG

Nab paclitaxel

Given by IV (vein)

DRUG

IM156

Given by PO

Trial Locations (1)

77030

MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER